Trials / Completed
CompletedNCT05828212
Evaluate the Safety and Efficacy of CAR-T Cells in the Treatment of R/R Neuromyelitis Optica
A Study on the Safety and Efficacy of Chimeric Antigen Receptor T Cells in the Treatment of Recurrent/Refractory Neuromyelitis Optica
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 9 (actual)
- Sponsor
- Zhejiang University · Academic / Other
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
This is a single-arm, open-label, single-center, phase I study. The primary objective is to evaluate the safety of CD19 CAR-T therapy for patients with relapsed or refractory Neuromyelitis Optica, and to evaluate the pharmacokinetics of CD19 CAR-T in patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CAR-T cells injection | CAR-T cells in the treatment of R/R neuromyelitis optica |
Timeline
- Start date
- 2023-05-15
- Primary completion
- 2025-07-30
- Completion
- 2025-07-30
- First posted
- 2023-04-25
- Last updated
- 2025-08-11
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05828212. Inclusion in this directory is not an endorsement.